HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 01:46:08 2024-06-05 pm EDT | ||
| 7.22 EUR | +1.83% |
|
| Current month | +3.65% | ||
| 1 month | +6.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 7.22 | +1.83% |
| 24-06-04 | 7.09 | +1.29% |
| 24-06-03 | 7 | +2.34% |
| 24-05-31 | 6.84 | +2.86% |
| 24-05-30 | 6.65 | +2.15% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 01:46 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXU |
| ISIN | DE000HR5TXU0 |
| Date issued | 2021-02-25 |
| Strike | 6,388 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.22 € |
|---|---|
| Lowest since issue | 1.22 € |
| Spread | 0.04 € |
| Spread % | 0.55% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
172.9
USD
Spread / Average Target
+9.02%
- Stock Market
- Certificates
- Certificat
